Results from a trial of OncoDxRx’s OncoMRD (Monitoring Residual Disease) test showed the company seems to be on track with its residual tumor monitoring test. OncoMRD test is designed to find any last remaining cells after cancer treatment. In the pilot study, the OncoMRD test achieved a high sensitivity and specificity in post-surgical checks and during the surveillance monitoring period.

“We’re thrilled to bring our OncoMRD solution to the rapidly growing molecular residual disease market, helping more patients get access to critical, high-quality testing,” said OncoDxRx.

“These data demonstrate the strong performance of OncoMRD. Building on the foundation of patient-derived gene expression signature and decades of expertise and knowhow, OncoDxRx is well positioned to lead the way with its commercial and operational partners, to ensure patients across the U.S. will have access to OncoMRD testing.”

OncoMRD detects the presence of cancer-specific circulating cell-free mRNA (cfmRNA) in the blood. These overactive transcripts of functional genetic information are shed into the bloodstream by tumors as well as its non-tumor microenvirnment, their presence may indicate that cancer is present.

OncoMRD test leverages OncoDxRx’s in-house capabilities in liquid biopsy to offer a gene signature-informed MRD test for a personalized approach to detecting and monitoring residual cancer in patients with solid tumors. By identifying unique patterns of gene activities in cfmRNA and detecting a patient’s own cancer fingerprint from blood, the OncoMRD test may enable the detection of tumor activity (beyond DNA mutation) before, during, and after treatment. This critical information can guide therapy decisions and monitor for cancer recurrence.

OncoDxRx emphasized the accumulation of cancer threats that require the company to adapt. Announcing the update of OncoDxRx’s exclusive pipelines, the company also called for a “Precision Theranostics strategic awakening.”

“Let’s not fool ourselves, cancer will not be cured tomorrow or five years after”.

“The challenge today is to allow patients to withstand and enter any intervention from a position of benefit. The task tomorrow will be to give patients guarantees against any return of disease, as well as guarantees of no patient left behind,” OncoDxRx said.

“We will need to better identify actionable biomarkers, categorize them, and be able to validate them when the time comes, reinforcing drug response prediction on patient non-responders or when standard of care is exhausted,” the company emphasized.

Whatever one thinks of its ramifications, the fact remains that OncoDxRx has proven itself to be an enduring precision theranostics player with the creation, production, and operational use of exclusive gene signature-powered technology for precision oncology.